novel therapeutics - Robuta Search

https://amplificabio.com/ Amplifica - Novel Therapeutics for Hair Regrowth Mar 12, 2025 - Our aim is to help the millions of men and women who suffer from hair loss by providing a nature inspired and effective solution that can regrow hair. novel therapeutics for hair amplifica regrowth https://www.chop.edu/centers-programs/novel-therapeutics-bleeding-disorders-not-bleeding-program/resources Novel Therapeutics for Bleeding Disorders (NoT Bleeding) Program Resources | Children's Hospital of... children s hospital novel therapeutics bleeding disorders https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2017.00222/full Frontiers | Tick Bioactive Molecules as Novel Therapeutics: Beyond Vaccine Targets Tick - pathogen - host interactions have been closely studied to understand the molecular mechanisms of pathogen transmission for tick-borne diseases, includ... novel therapeutics frontiers tick bioactive molecules https://f2g.com/ Novel Therapeutics for Rare Fungal Infections | F2G F2G is transforming the fight against rare, invasive fungal infections by developing novel antifungals that give patients another chance at life. novel therapeutics fungal infections rare f2g https://pmc.ncbi.nlm.nih.gov/articles/PMC11099982/ Prurigo nodularis: new insights into pathogenesis and novel therapeutics - PMC Prurigo nodularis (PN) is an inflammatory skin condition characterized by intensely pruritic nodules on the skin. Patients with PN suffer from an intractable... prurigo nodularis novel therapeutics new insights pathogenesis https://www.chop.edu/centers-programs/novel-therapeutics-bleeding-disorders-not-bleeding-program/contact Contact The Novel Therapeutics for Bleeding Disorders (NoT Bleeding) Program | Children's Hospital... Use this form if you have a question about the Novel Therapeutics for Bleeding Disorders (NoT Bleeding) Program or about the services we offer at Children's... contact the novel therapeutics bleeding disorders https://attralus.com/ Novel Pan-Amyloid Removal (PAR) Therapeutics | Attralus Jan 12, 2026 - Our mission is to improve the lives of amyloidosis patients by developing transformational therapeutics focused on amyloid removal. novel pan amyloid removal par https://www.biospace.com/seneca-biopharma-and-qyuns-therapeutics-sign-term-sheet-for-global-licensing-of-novel-monoclonal-antibodies-for-treating-auto-immune-diseases Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal... Oct 31, 2019 - Seneca Biopharma, Inc. and Jiangsu QYuns Therapeutics Co., Ltd. jointly announce that they have entered into a non-binding term sheet for the licensing of... https://www.finanznachrichten.de/nachrichten-2026-02/67820691-atrium-therapeutics-launches-with-approximately-dollar-270-million-to-advance-novel-rna-medicines-for-rare-genetic-cardiomyopathies-008.htm Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for... Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR... https://www.businesswire.com/news/home/20241008352942/en/PsychoGenics-Awarded-an-NIH-Contract-to-Test-and-Identify-Novel-Therapeutics-for-Pain PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain PsychoGenics Inc. (PsychoGenics) today announced it has been awarded a contract by the National Institutes of Health (NIH) to test and identify novel investi... https://www.techtarget.com/pharmalifesciences/news/366607638/AstraZeneca-Accent-Therapeutics-to-Create-Novel-Cancer-Therapies AstraZeneca, Accent Therapeutics to Create Novel Cancer Therapies | TechTarget AstraZeneca and Accent Therapeutics partner to create novel cancer therapies to target RNA-modifying proteins (RMPs). astrazeneca accent therapeutics create novel https://www.biospace.com/press-releases/forx-therapeutics-initiates-first-in-human-trial-with-novel-anti-cancer-drug-forx-428-targeting-dna-damage-response FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA... first in human trial https://www.globenewswire.com/fr/news-release/2025/10/07/3162367/0/en/Coave-Therapeutics-demonstrates-superiority-of-its-novel-suprachoroidal-capsid-at-ESGCT-Congress-2025.html Coave Therapeutics demonstrates superiority of its novel Lead suprachoroidal capsid coAAV-SCS-01 demonstrated up to 26x outperformance of other capsids in targeting RPE-choroid and retinal cellscoAAV-SCS-01... therapeutics demonstrates superiority novel https://www.biospace.com/press-releases/innovo-therapeutics-announces-positive-phase-1-results-for-inv-101-a-novel-immuno-metabolic-modulator-for-autoimmune-diseases Innovo Therapeutics Announces Positive Phase 1 Results for INV-101, a Novel Immuno-Metabolic... https://www.biospace.com/skyline-therapeutics-receives-china-nmpa-s-approval-of-ind-for-skg0106-a-novel-intravitreally-delivered-aav-gene-therapy-candidate-for-neovascular-age-related-macular-degeneration Skyline Therapeutics Receives China NMPA's Approval of IND for SKG0106, a Novel Intravitreally... Oct 19, 2023 - Skyline Therapeutics announced that the China National Medical Products Administration has approved its Investigational New Drug application for SKG0106, a... https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-strategic-collaboration-with-merck-to-discover-novel-rna-targeting-small-molecules-for-neurological-disorders-302531301.html Skyhawk Therapeutics Announces Strategic Collaboration with Merck to Discover Novel RNA-Targeting... /PRNewswire/ -- Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today announces a... strategic collaboration https://www.biospace.com/vitrac-therapeutics-to-present-phase-1-clinical-trial-design-on-novel-aurora-kinase-a-inhibitor-vic-1911-and-g12c-inhibitor-sotorasib-for-kras-g12c-mutant-non-small-cell-lung-cancer-at-the-2023-asco-annual-meeting VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor,... Jun 5, 2023 - VITRAC Therapeutics, LLC presented a poster on the Phase 1a/1b clinical trial of aurora kinase A inhibitor, VIC-1911, as monotherapy and in combination with... phase 1 clinical trial https://www.januxrx.com/ Janux Therapeutics | Novel T Cell Immunotherapies Oct 31, 2025 - Janux is developing novel immunotherapies that selectively modulate T cells to fight cancer and autoimmune diseases without causing systemic safety issues. t cell therapeutics novel immunotherapies https://www.biospace.com/relmada-therapeutics-announces-filing-of-clinical-trial-application-in-canada-for-novel-oral-formulations-of-buprenorphine Relmada Therapeutics Announces Filing Of Clinical Trial Application In Canada For Novel Oral... https://www.businesswire.com/news/home/20211103005279/en/Autobahn-Therapeutics-Announces-New-Preclinical-Data-Supporting-its-Novel-Brain-Targeting-Platform-for-the-Development-of-Therapeutics-for-CNS-Disorders Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform... Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for CNS Disorders https://www.utmb.edu/bmb/seminars/academic-year/2024/02/01/default-calendar/molecule-allosteric-agonists-of-integrin-cd11b-as-novel-therapeutics-for-autoimmune-diseases Molecule Allosteric Agonists of Integrin CD11b as Novel Therapeutics for Autoimmune Diseases Speaker: Dr. Vineet Gupta, The University of Texas Medical Branch Host: Krishna Rajarathnam, Ph.D. https://www.newswire.ca/news-releases/xenon-to-collaborate-with-genentech-on-discovery-of-novel-targeted-pain-therapeutics-509416811.html Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics /CNW/ - Xenon today announced a strategic alliance with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to discover and develop... https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-research-collaboration-with-takeda-for-novel-non-viral-in-vivo-gene-therapies-301397569.html Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene... /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform... https://www.alphinatx.com/ Alphina Therapeutics - Redefining precision oncology for ADCs with a novel payload Nov 3, 2025 - Alphina Therapeutics is a biotechnology company established by a team of world-leading experts in DNA repair and metabolic lethality. precision oncology with a alphina therapeutics redefining https://www.saniarx.com/ Sania Therapeutics | Novel medicines for neural circuit dysfunctions Built for precision, designed for patients. Sania [sah-nee-ah] combines precision delivery with neuromodulation to redefine the treatment of neural circuit... neural circuit sania therapeutics novel medicines https://www.businesswire.com/news/home/20251209988664/en/Ventus-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-VENT-03-a-Novel-Small-Molecule-cGAS-Inhibitor-in-Patients-with-Lupus Ventus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel... Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for immunological, inflammatory, and neurological ... https://www.prnewswire.com/news-releases/soin-therapeutics-completes-formulation-development-of-novel-low-dose-naltrexone-tablet-to-treat-complex-regional-pain-syndrome-301450834.html Soin Therapeutics Completes Formulation Development of Novel Low Dose Naltrexone Tablet to Treat... /PRNewswire/ -- Soin Therapeutics, a biotechnology company based in Dayton, OH, has completed the formulation development work of their novel, proprietary... low dose naltrexone https://www.biospace.com/b-centauri-therapeutics-ltd-b-to-develop-novel-anti-infective-therapeutics Centauri Therapeutics Ltd To Develop Novel Anti-Infective Therapeutics - BioSpace to develop anti infective centauri therapeutics ltd https://www.businesswire.com/news/home/20241116643792/en/Encora-Therapeutics-Successfully-Completes-ULTRE-Clinical-Trial-Evaluating-Novel-Wrist-Worn-Wearable-for-Essential-Tremor Encora Therapeutics Successfully Completes ULTRE Clinical Trial Evaluating Novel Wrist-Worn... Encora Therapeutics is pleased to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. This stud... clinical trial therapeutics successfully completes ultre https://www.businesswire.com/news/home/20260503595444/en/UCB-to-Acquire-Candid-Therapeutics-Building-Upon-Its-Existing-Immunology-Pipeline-With-Novel-T-cell-Engagers UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel... UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a priva... https://www.oncobonetherapeutics.com/ OncoBone Therapeutics - Novel therapies for bone metastasizing cancers Feb 23, 2026 - OncoBone Therapeutics develops novel therapies for cancer patients with bone metastases therapeutics novel therapies bone metastasizing https://www.biospace.com/press-releases/sensible-biotechnologies-slashes-time-taken-to-optimize-novel-cell-based-mrna-therapeutics-by-more-than-90-with-ai-platform-built-on-nvidia-technology Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More... https://www.prnewswire.com/news-releases/accent-therapeutics-presents-data-reinforcing-therapeutic-potential-of-novel-kif18a-inhibitor-atx-295-at-the-2026-american-association-for-cancer-research-annual-meeting-302743812.html Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor,... /PRNewswire/ -- Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, today presented... accent therapeutics presents data reinforcing https://www.businesswire.com/news/home/20220126005858/en/Ostentus-Therapeutics-Inc.-and-City-of-Hope-to-Initiate-Studies-of-Novel-OST-Natural-Products-for-Treatment-of-Leukemia-and-Other-Cancers Ostentus Therapeutics, Inc., and City of Hope to Initiate Studies of Novel OST Natural Products for... Ostentus Therapeutics, Inc., has entered into a Sponsored Research Agreement with City of Hope, a world-renowned cancer treatment and research organization a... https://www.globenewswire.com/fr/news-release/2020/06/16/2048847/0/en/renibus-therapeutics-announces-publication-of-a-novel-stress-test-for-assessing-antioxidant-defenses-in-chronic-kidney-disease.html Renibus Therapeutics Announces Publication of a Novel --In a phase 1 study, RBT-6 was administered to study participants with moderate to severe chronic kidney disease (CKD) and showed an increase in... therapeutics announces publication novel https://www.businesswire.com/news/home/20221130005077/en/Corner-Therapeutics-to-Present-Pre-Clinical-Data-on-their-Novel-Dendritic-Cell-Hyperactivation-Platform-at-the-4th-Inflammasome-Therapeutics-Summit Corner Therapeutics to Present Pre-Clinical Data on their Novel Dendritic Cell Hyperactivation... Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost the intelligence of the natural immune response to disease, today ... https://www.biospace.com/candel-therapeutics-presents-novel-biomarker-data-demonstrating-immune-activation-after-administration-of-can-3110-in-patients-with-recurrent-high-grade-glioma Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After... Nov 12, 2021 - Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced... candel therapeutics presents novel biomarker https://101therapeutics.com/ 101 Therapeutics - Discovering Novel Therapeutics 101 Therapeutics discovers and develops effective, easy-to-use, and well-tolerated therapies across oncology, autoimmune, metabolic, and rare diseases. 101 therapeutics discovering novel https://www.biospace.com/nektar-therapeutics-announces-phase-1b-data-for-novel-t-regulatory-cell-stimulator-nktr-358-ly3471851-in-patients-with-atopic-dermatitis Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358... https://www.frontiersin.org/research-topics/29437/novel-modalities-in-cancer-diagnostics-and-therapeutics/magazine Novel Modalities in Cancer Diagnostics and Therapeutics | Frontiers Research Topic cancer diagnostics novel modalities therapeutics frontiers https://www.biospace.com/fairjourney-biologics-enters-antibody-discovery-agreement-with-pandion-therapeutics-using-novel-discovery-platforms FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics using novel... Nov 23, 2020 - Diverse panel of novel target binders from FairJourney Biologics and IONTAS will be used to uncover functional antibodies to advance autoimmune and... antibody discovery biologics enters https://www.businesswire.com/news/home/20250108315425/en/Resilience-Partners-with-Parvus-Therapeutics-for-Development-and-Manufacturing-of-PVT401-a-Novel-Autoimmune-Drug-Candidate-for-IBD Resilience Partners with Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel... National Resilience, Inc. (Resilience), a technology-driven biomanufacturing leader dedicated to broadening access to complex medicines, today announced the ... https://www.biospace.com/jasper-therapeutics-to-present-at-the-oppenheimer-novel-targets-in-immunology-summit Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit - BioSpace Jun 18, 2024 - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) today announced today announced that its management will present at the Oppenheimer Novel Targets in... https://www.prnewswire.com/news-releases/novel-long-rna-manufacturing-approaches-for-advancing-rna-therapeutics-upcoming-webinar-hosted-by-xtalks-302575181.html Novel Long RNA Manufacturing Approaches for Advancing RNA Therapeutics, Upcoming Webinar Hosted by... In this free webinar, learn how innovative long RNA manufacturing approaches can drive the development of next-generation RNA medicines. Attendees will... https://nuvigtx.com/ Novel Therapies for Chronic Autoimmune Diseases | Nuvig Therapeutics Sep 9, 2025 - Our mission is to bring innovative and transformational therapies to patients with chronic autoimmune disease, via induction of mechanisms that restore immune... autoimmune diseases novel therapies chronic therapeutics https://www.biospace.com/torreypines-therapeutics-inc-initiates-phase-i-clinical-trial-of-ngx426-a-novel-oral-therapy-for-migraine-and-neuropathic-pain TorreyPines Therapeutics, Inc. Initiates Phase I Clinical Trial Of NGX426, A Novel Oral Therapy For... phase i clinical trial https://www.perseveretherapeutics.com/ Persevere - Novel Cancer Therapeutic - Giving Patients New Hope : Persevere Therapeutics Feb 26, 2026 - Persevere Therapeutics novel drug is focused on improving effectiveness of cancer treatments new hope persevere novel cancer therapeutic https://www.prnewswire.co.uk/news-releases/atp-launches-adendra-therapeutics-a-new-kind-of-immunotherapy-company-deploying-novel-insights-into-dendritic-cell-biology-with-53m-series-a-891205013.html ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights... /PRNewswire/ -- ATP (Apple Tree Partners), a leader in life sciences venture capital, today announced the launch of Adendra Therapeutics Ltd. ("Adendra"), a... https://www.mdanderson.org/newsroom/archived-news/md-anderson-and-deer.h00-159142089.html ARCHIVED: create Vescor LLC to develop novel therapeutics based on inhibiting autophagy for... Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by The University of... https://www.news-medical.net/news/20250115/Pheno-Therapeutics-receives-clinical-trial-authorization-for-novel-multiple-sclerosis-therapeutic.aspx Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeutic Jan 15, 2025 - Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological... clinical trial multiple sclerosis pheno therapeutics receives https://anagramtx.com/ Developing Novel Oral Enzyme Therapies for Malabsorption Diseases | Anagram Therapeutics Anagram Therapeutics is pioneering novel orally delivered enzyme therapeutics to treat serious diseases caused by malabsorption syndromes and nutrient... developing novel oral enzyme therapies https://www.prnewswire.com/news-releases/mosanna-therapeutics-launches-with-80-million-to-advance-novel-nighttime-nasal-spray-for-obstructive-sleep-apnea-302474885.html Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for... /PRNewswire/ -- Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of $80 million in... https://www.biospace.com/adc-therapeutics-submits-its-first-ind-for-a-novel-antibody-drug-conjugate-against-lymphomas ADC Therapeutics Submits Its First IND For A Novel Antibody Drug Conjugate Against Lymphomas -... https://www.businesswire.com/news/home/20231127925735/en/Avilar-Therapeutics-Receives-U.S.-Patent-for-Novel-Extracellular-Protein-Degraders Avilar Therapeutics Receives U.S. Patent for Novel Extracellular Protein Degraders Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that the U.S. Patent and Trademark Office issu... u s patent therapeutics receives https://www.businesswire.com/news/home/20250204089126/en/SiteOne-Therapeutics-Announces-Positive-Phase-1-Clinical-Data-for-STC-004-a-Novel-NaV1.8-Inhibitor-in-Development-for-the-Non-Opioid-Treatment-of-Pain SiteOne Therapeutics Announces Positive Phase 1 Clinical Data for STC-004, a Novel NaV1.8 Inhibitor... SiteOne Therapeutics Announces Positive Phase 1 Clinical Data for STC-004, a Novel NaV1.8 Inhibitor in Development for Non-Opioid Pain Treatment https://www.biospace.com/b-amphivena-therapeutics-b-to-present-data-on-novel-cancer-immunotherapy-at-2015-asco-annual-meeting Amphivena Therapeutics To Present Data On Novel Cancer Immunotherapy At 2015 ASCO Annual Meeting -... https://vayunatx.com/ Vayuna Therapeutics | Novel Cancer & ADC Medicines therapeutics novel cancer adc medicines https://www.businesswire.com/news/home/20220503005444/en/Genesis-Therapeutics-Announces-Strategic-Collaboration-with-Lilly-to-Discover-Novel-Therapies-Using-the-Genesis-Molecular-AI-Platform Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using... Genesis Therapeutics, a company pioneering artificial intelligence technologies to create medicines for patients with severe and unmet medical conditions, an... strategic collaboration https://www.businesswire.com/news/home/20200529005068/en/Immune-Onc-Therapeutics-IND-Application-for-First-In-Human-Trial-of-IO-202-a-Novel-Antibody-for-the-Treatment-of-Acute-Myeloid-Leukemia-Receives-FDA-Clearance Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for... Immune-Onc Therapeutics IND Application for FIH Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance https://www.exeter.ac.uk/study/funding/award/?id=5625 Novel phage-based therapeutics against drug-resistant bacteria. MRC GW4 BioMed DTP PhD studentship... The GW4 BioMed2 MRC DTP is offering up to 17 funded studentships across a range of biomedical disciplines, with a start date of October 2026.